Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10089378 | 0.94 | CYP2D6 (0.36) | CYP2D6CYP2C19CYP1A2CYP2C9CYP3A4 | |
| SCHEMBL10089342 | 0.94 | CYP2D6 (0.36) | CYP2D6CYP2C19CYP1A2CYP2C9CYP3A4 | |
| SCHEMBL10089374 | 0.87 | CYP2C19 (0.40) | CYP2D6CYP2C19CYP1A2CYP2C9TSHR | |
| SCHEMBL10089377 | 0.84 | CYP2D6 (0.37) | CYP2D6CYP2C19CYP1A2CYP2C9CYP3A4 | |
| SCHEMBL223247 | 0.83 | CYP2C19 (0.42) | CYP2D6CYP2C19CYP1A2CYP2C9CYP3A4 | |
| SCHEMBL5034217 | 0.83 | CYP2C19 (0.42) | CYP2D6CYP2C19CYP1A2CYP2C9CYP3A4 | |
| SCHEMBL14781410 | 0.82 | PTPN5 (0.48) | CYP2D6CYP2C19CYP1A2CYP2C9CYP3A4 | |
| SCHEMBL14471347 | 0.81 | CYP2D6 (0.35) | CYP2D6CYP2C19CYP1A2CYP2C9CYP3A4 | |
| SCHEMBL14702266 | 0.81 | CYP2C19 (0.40) | CYP2D6CYP2C19CYP1A2CYP2C9CYP3A4 | |
| SCHEMBL10089371 | 0.80 | CYP1A2 (0.39) | CYP2D6CYP2C19CYP1A2CYP2C9HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383753-B2 | Polydentate heteroatom ligand containing metal complexes, catalysts and methods of making and using the same | DOW GLOBAL TECHNOLOGIES, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383753-B2 | Polydentate heteroatom ligand containing metal complexes, catalysts and methods of making and using the same | DOW GLOBAL TECHNOLOGIES, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120029159-A1 | POLYDENTATE HETEROATOM LIGAND CONTAINING METAL COMPLEXES, CATALYSTS AND METHODS OF MAKING AND USING THE SAME | DOW GLOBAL TECHNOLOGIES LLC (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120029159-A1 | POLYDENTATE HETEROATOM LIGAND CONTAINING METAL COMPLEXES, CATALYSTS AND METHODS OF MAKING AND USING THE SAME | DOW GLOBAL TECHNOLOGIES LLC (US) | 2012-02-02 | — | — | US | disclosed |
| US-8071701-B2 | Polydentate heteroatom ligand containing metal complexes, catalysts and methods of making and using the same | DOW GLOBAL TECHNOLOGIES LLC (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071701-B2 | Polydentate heteroatom ligand containing metal complexes, catalysts and methods of making and using the same | DOW GLOBAL TECHNOLOGIES LLC (US) | 2011-12-06 | — | — | US | disclosed |
| US-20090221770-A1 | POLYDENTATE HETEROATOM LIGAND CONTAINING METAL COMPLEXES, CATALYSTS AND METHODS OF MAKING AND USING THE SAME | DOW GLOBAL TECHNOLOGIES INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221770-A1 | POLYDENTATE HETEROATOM LIGAND CONTAINING METAL COMPLEXES, CATALYSTS AND METHODS OF MAKING AND USING THE SAME | DOW GLOBAL TECHNOLOGIES INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2007075299-A2 | POLYDENTATE HETEROATOM LIGAND CONTAINING METAL COMPLEXES, CATALYSTS AND METHODS OF MAKING AND USING THE SAME | DOW GLOBAL TECHNOLOGIES INC. (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221770-A1 | POLYDENTATE HETEROATOM LIGAND CONTAINING METAL COMPLEXES, CATALYSTS AND METHODS OF MAKING AND USING THE SAME | PICALM, PARG, POLM | CYP2D6 2941/4885CYP2C19 4184/4885CYP1A2 4502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.